Abstract
To initiate the innate immune response, Toll-like receptors (TLRs) associate with cytoplasmic adaptor proteins through TIR (Toll/interleukin-1 receptor) domain interactions. The four principal signaling adaptor proteins include MyD88, MAL, TRIF and TRAM, and the fifth protein SARM, involved in negative regulation of TLR pathways, is usually considered a part of the TIR domain-containing adaptor protein group. Other TIR domain-containing proteins have also been shown to regulate these signaling pathways, including ST2 and SIGIRR, as well as several bacterial and viral TIR domain-containing proteins that modulate these pathways as virulence factors. TLR pathways and the adaptor proteins are associated with a number of diseases, including infection, sepsis, inflammatory, allergic and autoimmune diseases and cancer. We review our current understanding of the structure and function of adaptor proteins and their regulatory proteins, their association with disease and their potential as therapeutic targets in human disease.
Keywords: Toll-like receptors (TLRs), TIR (Toll/interleukin-1 receptor) domain, adaptor proteins, Therapeutic Targets, signaling adaptor proteins, PAMPs, ligand-receptor interaction, ST2, SIGIRR, signaling pathways.
Current Drug Targets
Title:Adaptors in Toll-Like Receptor Signaling and their Potential as Therapeutic Targets
Volume: 13 Issue: 11
Author(s): Thomas Ve, Nicholas J. Gay, Ashley Mansell, Bostjan Kobe and Stuart Kellie
Affiliation:
Keywords: Toll-like receptors (TLRs), TIR (Toll/interleukin-1 receptor) domain, adaptor proteins, Therapeutic Targets, signaling adaptor proteins, PAMPs, ligand-receptor interaction, ST2, SIGIRR, signaling pathways.
Abstract: To initiate the innate immune response, Toll-like receptors (TLRs) associate with cytoplasmic adaptor proteins through TIR (Toll/interleukin-1 receptor) domain interactions. The four principal signaling adaptor proteins include MyD88, MAL, TRIF and TRAM, and the fifth protein SARM, involved in negative regulation of TLR pathways, is usually considered a part of the TIR domain-containing adaptor protein group. Other TIR domain-containing proteins have also been shown to regulate these signaling pathways, including ST2 and SIGIRR, as well as several bacterial and viral TIR domain-containing proteins that modulate these pathways as virulence factors. TLR pathways and the adaptor proteins are associated with a number of diseases, including infection, sepsis, inflammatory, allergic and autoimmune diseases and cancer. We review our current understanding of the structure and function of adaptor proteins and their regulatory proteins, their association with disease and their potential as therapeutic targets in human disease.
Export Options
About this article
Cite this article as:
Ve Thomas, J. Gay Nicholas, Mansell Ashley, Kobe Bostjan and Kellie Stuart, Adaptors in Toll-Like Receptor Signaling and their Potential as Therapeutic Targets, Current Drug Targets 2012; 13 (11) . https://dx.doi.org/10.2174/138945012803530260
DOI https://dx.doi.org/10.2174/138945012803530260 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member:
Current Diabetes Reviews Effects of Green Tea on Iron Accumulation and Oxidative Stress in Livers of Iron-Challenged Thalassemic Mice
Medicinal Chemistry Cardio-vascular Activity of Catestatin: Interlocking the Puzzle Pieces
Current Medicinal Chemistry New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Na+,K+-ATPase as a Target for Treatment of Tissue Fibrosis
Current Medicinal Chemistry Current Advances in the Synthesis and Antitumoral Activity of SIRT1-2 Inhibitors by Modulation of p53 and Pro-Apoptotic Proteins
Current Medicinal Chemistry Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Wogonin and Alleviation of Hyperglycemia <i>via</i> Inhibition of DAG Mediated PKC Expression. A Brief Insight
Protein & Peptide Letters Role of miRNAs in Muscle Stem Cell Biology: Proliferation, Differentiation and Death
Current Pharmaceutical Design Epidemiology and Risk Factors of Cerebral Ischemia and Ischemic Heart Diseases: Similarities and Differences
Current Cardiology Reviews Understanding the Cardiovascular Actions of Soy Isoflavones: Potential Novel Targets for Antihypertensive Drug Development
Cardiovascular & Hematological Disorders-Drug Targets Editorial [Hot Topic:Metabolic Therapy: An Important Therapeutic Option for the Treatment of Cardiovascular Diseases (Executive Editors: G.M.C. Rosano and G. Barbaro)]
Current Pharmaceutical Design Meet Our Editor:
Current Cardiology Reviews The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism Sterol 14α-Demethylase from Trypanosomatidae Parasites as a Promising Target for Designing New Antiparasitic Agents
Current Topics in Medicinal Chemistry Updates on HCN Channels in the Heart: Function, Dysfunction and Pharmacology
Current Drug Targets Platelet and Soluble Glycoprotein VI - Novel Applications in Diagnosis and Therapy
Current Drug Targets Updated Electrocardiographic Classification of Acute Coronary Syndromes
Current Cardiology Reviews MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy
Current Gene Therapy Cutaneous Complications of Anderson-Fabry Disease
Current Pharmaceutical Design